Key Highlights

● Sanofi's U.S.-listed shares rose on Friday, October 30, 2026.

● The drugmaker beat third-quarter expectations.

● It raised its full-year 2026 sales forecast.

● Health care hit a record high on a sharply lower day.

Sanofi (NASDAQ:SNY) moved higher on Friday, October 30, 2026, after the Paris-based pharmaceutical group reported third-quarter results that beat expectations and raised its sales forecast for 2026, according to a market headline. Its American depositary shares rose on a day when the Nasdaq Composite fell 747.73 points to 25,437.00, its worst session since June 5.

The size of Sanofi's gain was not specified in reports on the session, but the direction stood out against a broad selloff in technology. Third-quarter sales rose solidly from a year earlier, according to market data.

A beat and a higher outlook

The core of Sanofi's report was simple: results came in ahead of expectations, and the company raised its full-year sales forecast.

Sanofi is one of Europe's largest drugmakers, with a portfolio spanning immunology, vaccines, rare diseases and general medicines. It has a long-running Partnership with Regeneron Pharmaceuticals (NASDAQ:REGN), which includes the jointly developed eczema and asthma drug Dupixent. A raised sales forecast this late in the year gives investors a firmer read on how the company expects 2026 to finish.

The Regeneron connection

That partnership was also in the news. Regeneron, Sanofi's alliance partner, was the S&P 500's top gainer on Friday after reporting third-quarter Revenue of $5.12 billion, well above the $4.54 billion estimate, and non-GAAP Earnings of $20.07 a share against a $16.24 forecast. Market data cited $1 billion upfront from an expanded Sanofi deal as part of Regeneron's news, along with an FDA approval for a product called Pasatru. Market reports said that Regeneron raised its full-year outlook.

The two companies' expanded alliance tied the day's biggest health care stories together, with both partners posting gains.

A record day for health care

Sanofi's rise was part of a broad rally in health care, which hit a record high, according to market data. Investors rotated out of AI, chip and megacap technology stocks and into energy, consumer staples, health care and utilities.

AstraZeneca (NASDAQ:AZN), another European drugmaker with U.S.-listed shares, rose after a third-quarter beat with double-digit oncology growth, according to a market headline. Gilead Sciences (NASDAQ:GILD) gained after non-GAAP earnings of $2.55 a share topped forecasts, and AbbVie (NYSE:ABBV), Johnson & Johnson (NYSE:JNJ), Pfizer (NYSE:PFE), Eli Lilly (NYSE:LLY) and Cardinal Health reached 52-week highs.

The rotation came as the technology sector reeled. Intel (NASDAQ:INTC)'s weak fourth-quarter outlook and warning of cash burn sent its shares to a record one-day decline and dragged the Philadelphia Semiconductor index down to 10,688.80. Amazon (NASDAQ:AMZN) reported trailing 12-month free Cash Flow of negative $42.4 billion as AI spending ballooned. The S&P 500 fell 140.32 points to 7,580.07, and the Dow Jones Industrial Average lost 572.25 points to 51,770.31.

Other pressures included oil above $100, a reported $6.3 billion hack at crypto exchange Binance, and a hawkish Federal Reserve, with futures pricing a likely December rate hike.

What to watch

Investors will look for fuller detail on Sanofi's raised 2026 sales outlook, including which products are driving the increase, as well as further information on the expanded alliance with Regeneron.

Health care earnings continue next week, with Pfizer reporting on Tuesday, November 3, the same day as the U.S. midterm elections. The October jobs report on Friday, November 6, will round out the week. Whether the rotation into health care continues if technology stocks stabilize will be a key question for the sector.